85-1556-96 [取扱停止]Insulin-Like Growth Factor Binding Protein 1, Recombinant, Human (IGFBP1) 25ug I7661-16B9

※お見積書はカートで印刷できます

冷凍 保管・搬送時に冷凍が必要な商品です。

特徴

  • The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and at least four additional low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-transitional modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.
  • Human IGFBP-1 cDNA encodes a 259 amino acid (aa) residue precursor protein with a putative 25 aa residue signal peptide that is processed to generate the 234 aa residue mature protein. IGFBP-1 contains an integrin receptor recognition sequence (RGD sequence) but lacks potential N-linked glycosylation sites. IGFBP-1 is expressed in liver, decidua, kidneys and is the most abundant IGFBP in amniotic fluid. Serum levels of IGFBP-1 are lowest after meals. Hepatocyte production of IGFBP-1 is regulated at the transcriptional level due to the affects of insulin and corticosteriods. IGFBP-1 binds equally well to IGF-I and IGF-II, with phosphorylated forms of IGFBP-1 exhibiting higher binding affinities.
  • Source:Recombinant corresponding to aa26-259 from human Insulin-Like Growth Factor Binding Protein 1 expressed in NSO cells (P08833).
  • N­terminal Sequence:Ala26
  • SDS-PAGE:32kD, reducing conditions
  • Biological Activity:Measured by its ability to inhibit the biological activity of IGF-I or IGF­II on MCF­7 human breast adenocarcinoma cells. The ED50 for this effect is typically 1-4ug/ml in the presence of 6ng/ml recombinant human IGF­I.
  • Storage and Stability:Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with PBS. Aliquot and store at -20°C. Reconstituted product is stable for 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

仕様

  • Size:25ug
  • Source Antigen:Recombinant, Human (NSO cells)
  • Grade:Highly Purified
  • Purity:≥97% by SDS-PAGE under reducing conditions and visualized by silver stain. Endotoxin: ≤1.0EU/ug (LAL)
  • Form:Supplied as a lyophilized powder from PBS, pH 7.4. Reconstitute with 250ul sterile PBS.
  • Molecular Weight Non Ab:25
  • Swiss Prot Number:P08833
  • EU Commodity Code:30021019
  • この商品は法規制を確認しておりません。(法規制によって販売できない場合もございます)
  • 製品の仕様は予告なく変更になる場合がございます。最新仕様はメーカーホームページをご確認ください。
  • 【試薬に関するお問合せ】
  • アズワン株式会社 試薬・プロセス材料グループ
  • TEL:06-6447-8641
  • FAX:06-6447-8642
  • E-mail:[email protected]
アズワン品番
85-1556-96
型番
I7661-16B9
入り数
1個
標準価格
225,000円(税抜)
WEB価格
-円
取扱停止
アズワン在庫 [?]
数量

※お気に入り機能はログイン後にご利用いただけます

よくあるご質問

よくあるご質問(FAQ)

掲載カタログ情報

掲載カタログ名 掲載ページ

次の商品を登録しました。

商品計:

お買い物を続ける カートを見る